A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Na ïve Chronic Kidney Disease Patients Not on Dialysis
Conclusion: Roxadustat increased and maintained Hb in ESA-na ïve, partially iron-depleted NDD-CKD patients with anemia.Nephron
Source: Nephron - Category: Urology & Nephrology Source Type: research
More News: Anemia | Chronic Kidney Disease | Common Cold | Dialysis | Hypertension | Iron | Japan Health | Study | Urology & Nephrology